Primary Ovarian Mucinous Carcinoma: A Diagnosis Defined as Much by Exclusion as by Recognition

What It Is and Where It Sits in Current Classification

Mucinous carcinoma of the ovary is a recognized subtype of ovarian epithelial malignancy in the 5th edition of the WHO Classification of Female Genital Tumours [1]. It is characterized by neoplastic epithelium resembling that of the gastrointestinal tract, so-called gastrointestinal (GI)-type mucinous epithelium, arranged in glands and cysts and demonstrating invasive growth.

Two facts should anchor any discussion of this entity. First, primary ovarian mucinous carcinoma is rare. Many tumors that appear to be mucinous carcinomas of the ovary are, on careful workup, metastases to the ovary from other organs: in a national population-based registry series roughly 15% of ovarian malignancies were secondary tumors, with the gastrointestinal tract the most common source [2][3]. Second, because of that reality, the diagnosis is defined as much by what it is not, a metastasis, as by its own intrinsic features. This dual character shapes the entire diagnostic approach and is the reason a pathologist must proceed methodically rather than accept a mucinous ovarian mass as primary at face value.

Mucinous neoplasms of the ovary span a biological continuum, from benign cystadenoma through borderline tumors to invasive carcinoma. Mucinous carcinoma occupies the malignant end of that spectrum, distinguished by the presence of stromal invasion.

How a Pathologist Recognizes It: Morphology → IHC → Molecular

The diagnostic sequence matters, and it proceeds in a deliberate order.

Morphology comes first. The tumor is composed of GI-type mucinous epithelium, tall columnar cells with apical mucin, sometimes with goblet-cell differentiation, forming glands and cystic spaces. The critical morphologic determination is the pattern of invasion, which the WHO framework describes in two forms [1]:

• Expansile (confluent) invasion, in which glands become so crowded and back-to-back that intervening stroma is effaced, producing a labyrinthine or confluent glandular proliferation without an obvious desmoplastic response.
• Infiltrative invasion, in which malignant glands, cell clusters, or single cells frankly infiltrate the stroma, often eliciting a desmoplastic reaction.

Recognizing invasion, and distinguishing it from the crowded but non-invasive architecture of a borderline tumor, is the first intellectual task. But morphology alone cannot settle the central question of primary versus metastatic origin, because a metastatic GI adenocarcinoma may closely mimic a primary ovarian mucinous tumor.

Immunohistochemistry is the second step, deployed specifically to address origin. The immunophenotype associated with primary ovarian mucinous carcinoma includes [1]:

• CK7 positive, with CK20 variable, a pattern that leans toward, but does not by itself prove, an ovarian (or upper-GI/pancreaticobiliary) origin. In comparative IHC series, diffuse CK7 is the strongest single discriminator while CK20 is the weakest, which is why CK20 is increasingly replaced by SATB2 in the mucinous primary-versus-metastasis panel [4][5].
• PAX8 often negative, notable because PAX8 is a Müllerian marker positive in many other ovarian epithelial tumors; its frequent absence here shows the GI-type differentiation of this tumor. PAX8 functions as a second-line, context-dependent marker rather than a standalone discriminator in consensus reporting and comparative panels [5][6].
• SATB2 negative, which helps exclude a lower gastrointestinal (colorectal/appendiceal) metastasis; SATB2 is a sensitive and specific marker of colorectal/appendiceal origin [4][8]. One pitfall to keep in mind: SATB2 is positive in roughly 15% of ovarian endometrioid carcinomas, so a positive result is interpreted in panel context rather than read as proof of GI origin [4].
• WT1 negative, helping separate it from serous tumors, which are typically WT1 positive; WT1 is characteristically expressed in serous carcinoma (roughly 79, 97%) and negative in the non-serous histotypes, including mucinous [7].

The clinical note reinforces the practical panel: when a lower-GI or appendiceal metastasis is on the table, SATB2, CK20, and CDX2 are the workhorse markers, and a diffusely SATB2-positive, CK20-predominant profile should raise strong suspicion for a colorectal or appendiceal primary rather than an ovarian one [1][9]. The SATB2/CK7 discrimination is the T1-validated core of that panel [4][8], while CDX2 operates as a supporting second-line marker rather than an independent discriminator [9]. The evidence supports using immunohistochemistry as a directional tool that integrates with, but does not replace, morphology and clinical/radiologic correlation.

Molecular findings are the third layer. Primary ovarian mucinous carcinomas are associated with KRAS mutations, and a subset show HER2 (ERBB2) amplification [1]. These features are informative both biologically and, in the case of HER2, for therapy-class eligibility (discussed below). Molecular testing does not stand alone as a proof of primary origin, but it contributes to a coherent picture when integrated with morphology and IHC.

Grading and Classification

Grading of ovarian mucinous carcinoma is performed by architecture and cytologic atypia [1]. In practical terms, the assessment weighs the degree of glandular complexity and architectural disorder together with nuclear atypia and mitotic activity. This architecture/atypia-based approach is distinct from the binary low-grade/high-grade model used for serous carcinomas, and it reflects the different biology of the mucinous category. The pattern of invasion, expansile versus infiltrative, is itself part of the morphologic characterization and is documented as part of the diagnosis [1]. Interobserver reproducibility of the infiltrative-invasion assessment is only moderate (reported κ around 0.60), a reminder that the pattern call carries a measurable degree of subjectivity [10].

Why the Distinction Matters Clinically

The overriding clinical message is that excluding a metastasis is the critical task [1]. A GI-tract, appendiceal, or pancreaticobiliary adenocarcinoma metastatic to the ovary can masquerade as a primary ovarian mucinous carcinoma, and the two carry entirely different implications for staging, source-tumor evaluation, and management. Misclassifying a metastasis as an ovarian primary, or vice versa, sends the patient down the wrong diagnostic and management pathway. This is why the SATB2/CK20/CDX2 panel and correlation with clinical and radiologic findings are not optional refinements but essential components of the workup.

Certain morphologic and gross clues classically raise suspicion for metastasis, bilaterality and small size favor metastatic disease in many settings, and bilateral involvement has been documented in a large share of secondary ovarian tumors [2][3], but immunohistochemistry provides the more objective discriminating evidence in routine practice [1].

The HER2 finding carries therapeutic relevance [1]. A subset of mucinous ovarian carcinomas demonstrate HER2 (ERBB2) amplification, reported in roughly 18% of cases in one tissue series [11] and around 26% in a gene-expression cohort [12], so HER2 testing is meaningful in the diagnostic evaluation, identifying patients whose tumors fall into a category for which HER2-directed therapy classes may become relevant. This is a statement about drug-class eligibility as informed by a biomarker, not a recommendation of any specific treatment for any specific patient; management decisions belong to the treating clinical team.

A note on epistemic humility: the biology of ovarian mucinous carcinoma, including the frequency and prognostic weight of HER2 amplification and KRAS mutation, remains an area of ongoing study, and pathologists should interpret molecular results within the context of the full clinicopathologic picture rather than in isolation.

Summary

Primary ovarian mucinous carcinoma is a rare, recognized WHO5 subtype defined by GI-type mucinous epithelium and either expansile or infiltrative invasion [1]. Its diagnosis follows a disciplined sequence, morphology, then a targeted immunohistochemical panel (CK7/CK20, PAX8, SATB2, WT1) to interrogate origin, then molecular characterization (KRAS, HER2), with the exclusion of a GI or pancreaticobiliary metastasis as the central, non-negotiable task [1].

References

1. WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed. IARC, Lyon; 2020. ISBN 978-92-832-4504-9.
2. Bruls J, Simons M, Overbeek LI, Bulten J, Massuger LF, Nagtegaal ID. A national population-based study of ovarian malignancies gives insight in the origin of malignancies metastatic to the ovary. Virchows Arch. 2015;467(1):79, 86. PMID 25894432. doi:10.1007/s00428-015-1771-0.
3. de Waal YR, Thomas CM, Oei AL, Sweep FC, Massuger LF. Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer. 2009;19(7):1160, 1165. PMID 19823050. doi:10.1111/IGC.0b013e3181b33cce.
4. Meagher NS, Köbel M, Karnezis AN, et al. A combination of the immunohistochemical markers CK7 and SATB2 is sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol. 2019;32(12):1834, 1846. PMID 31239549. doi:10.1038/s41379-019-0302-0.
5. Strickland S, Wasserman JK, Giassi A, Djordjevic B, Parra-Herran C. Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms: a study of 29 cases. Int J Gynecol Pathol. 2016;35(3):191, 208. PMID 26535987. doi:10.1097/PGP.0000000000000238.
6. McCluggage WG, Judge MJ, Clarke BA, et al. Data set for reporting of ovarian, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol. 2015;28(8):1101, 1122. PMID 26089092. doi:10.1038/modpathol.2015.77.
7. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol. 2010;220(3):392, 400. PMID 19967725. doi:10.1002/path.2714.
8. Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35(7):937, 948. PMID 21677534. doi:10.1097/PAS.0b013e31821c3dae.
9. National Complete Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer (incl. mucinous histology), 2026. (Expert-consensus/evidence-summary; T3 attribution.)
10. Köbel M, Kang EY, et al. Interobserver reproducibility of the infiltrative pattern of invasion in mucinous ovarian carcinoma. Histopathology. 2024;84(7):1095, 1110. PMID 38155475. doi:10.1111/his.15128.
11. McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433. PMID 20003286. doi:10.1186/1471-2407-9-433.
12. Meagher NS, et al. Gene expression profiling of mucinous ovarian carcinoma: molecular characterization and prognostic features (NanoString/OTTA). Clin Cancer Res. 2022. PMID 36222710.